Prefilled certolizumab pegol (Cimzia®) syringes for self-use in the treatment of rheumatoid arthritis
J Rosa1,2, M Sabelli1,2, Enrique R Soriano1,21Rheumatology Section, Internal Medical Services, Hospital Italiano de Buenos Aires, and Fundacion P.M. Catoggio para el progreso de la Reumatologia; 2University Institute, School of Medicine, Hospital Italiano de Buenos Aires, ArgentinaAbstract: A new an...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/72b0760dc5a844239758bc6769708c53 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:72b0760dc5a844239758bc6769708c53 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:72b0760dc5a844239758bc6769708c532021-12-02T03:50:32ZPrefilled certolizumab pegol (Cimzia®) syringes for self-use in the treatment of rheumatoid arthritis1179-1470https://doaj.org/article/72b0760dc5a844239758bc6769708c532010-08-01T00:00:00Zhttp://www.dovepress.com/prefilled-certolizumab-pegol-cimziareg-syringes-for-self-use-in-the-tr-a5012https://doaj.org/toc/1179-1470J Rosa1,2, M Sabelli1,2, Enrique R Soriano1,21Rheumatology Section, Internal Medical Services, Hospital Italiano de Buenos Aires, and Fundacion P.M. Catoggio para el progreso de la Reumatologia; 2University Institute, School of Medicine, Hospital Italiano de Buenos Aires, ArgentinaAbstract: A new anti-tumor necrosis factor alpha (TNF-a) inhibitor with a novel mechanism of action has entered phase 3 trials in rheumatoid arthritis (RA). Certolizumab pegol (Cimzia®) is a humanized Fab' antibody fragment against TNF-a with a polyethylene glycol tail that prevents complement-dependent and antibody-dependent cell-mediated cytotoxicity or apoptosis. Four randomized clinical trials have been published so far. Reported results are similar to those published in previous studies with other TNF-a inhibitors, with ACR20, ACR50, and ACR70 responses of around 60%, 40%, and 20%, respectively, when combined with methotrexate and slightly lower when used as monotherapy. Safety was shown to be similar to that seen with TNF-a blockers and some cases of tuberculosis were seen in the trials, stressing the importance of a complete screening in these patients. Although we still need effectiveness and safety data in larger numbers of patients and longer follow-up, this new TNF inhibitor is a welcome addition to our current armamentarium for the treatment of RA.Keywords: certolizumab pegol, rheumatoid arthritis therapy, biologic therapies J RosaM SabelliEnrique R SorianoDove Medical PressarticleMedical technologyR855-855.5ENMedical Devices: Evidence and Research, Vol 2010, Iss default, Pp 25-31 (2010) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medical technology R855-855.5 |
| spellingShingle |
Medical technology R855-855.5 J Rosa M Sabelli Enrique R Soriano Prefilled certolizumab pegol (Cimzia®) syringes for self-use in the treatment of rheumatoid arthritis |
| description |
J Rosa1,2, M Sabelli1,2, Enrique R Soriano1,21Rheumatology Section, Internal Medical Services, Hospital Italiano de Buenos Aires, and Fundacion P.M. Catoggio para el progreso de la Reumatologia; 2University Institute, School of Medicine, Hospital Italiano de Buenos Aires, ArgentinaAbstract: A new anti-tumor necrosis factor alpha (TNF-a) inhibitor with a novel mechanism of action has entered phase 3 trials in rheumatoid arthritis (RA). Certolizumab pegol (Cimzia®) is a humanized Fab' antibody fragment against TNF-a with a polyethylene glycol tail that prevents complement-dependent and antibody-dependent cell-mediated cytotoxicity or apoptosis. Four randomized clinical trials have been published so far. Reported results are similar to those published in previous studies with other TNF-a inhibitors, with ACR20, ACR50, and ACR70 responses of around 60%, 40%, and 20%, respectively, when combined with methotrexate and slightly lower when used as monotherapy. Safety was shown to be similar to that seen with TNF-a blockers and some cases of tuberculosis were seen in the trials, stressing the importance of a complete screening in these patients. Although we still need effectiveness and safety data in larger numbers of patients and longer follow-up, this new TNF inhibitor is a welcome addition to our current armamentarium for the treatment of RA.Keywords: certolizumab pegol, rheumatoid arthritis therapy, biologic therapies |
| format |
article |
| author |
J Rosa M Sabelli Enrique R Soriano |
| author_facet |
J Rosa M Sabelli Enrique R Soriano |
| author_sort |
J Rosa |
| title |
Prefilled certolizumab pegol (Cimzia®) syringes for self-use in the treatment of rheumatoid arthritis |
| title_short |
Prefilled certolizumab pegol (Cimzia®) syringes for self-use in the treatment of rheumatoid arthritis |
| title_full |
Prefilled certolizumab pegol (Cimzia®) syringes for self-use in the treatment of rheumatoid arthritis |
| title_fullStr |
Prefilled certolizumab pegol (Cimzia®) syringes for self-use in the treatment of rheumatoid arthritis |
| title_full_unstemmed |
Prefilled certolizumab pegol (Cimzia®) syringes for self-use in the treatment of rheumatoid arthritis |
| title_sort |
prefilled certolizumab pegol (cimzia®) syringes for self-use in the treatment of rheumatoid arthritis |
| publisher |
Dove Medical Press |
| publishDate |
2010 |
| url |
https://doaj.org/article/72b0760dc5a844239758bc6769708c53 |
| work_keys_str_mv |
AT jrosa prefilledcertolizumabpegolcimziaampregsyringesforselfuseinthetreatmentofrheumatoidarthritis AT msabelli prefilledcertolizumabpegolcimziaampregsyringesforselfuseinthetreatmentofrheumatoidarthritis AT enriquersoriano prefilledcertolizumabpegolcimziaampregsyringesforselfuseinthetreatmentofrheumatoidarthritis |
| _version_ |
1718401603248062464 |